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KUALITI HIDUP DAN PENGALAMAN KESEJAHTERAAN KESIHATAN 
DALAM KALANGAN WANITA PENGHIDAP KANSER PAYUDARA 
METASTATIK YANG SEDANG MENJALANI KIMOTERAPI DI BEIJING: 
SUATU KAJIAN KAEDAH CAMPURAN 
 
ABSTRAK 
Kanser payudara metastatik (MBC) adalah satu keadaan kesihatan yang tidak boleh 
disembuhkan dan jangkamasa median kelangsungan hidup adalah 2 hingga 4 tahun 
selepas diagnosis. Penyelidikan setakat ini kurang memberi tumpuan kepada kualiti 
kehidupan (QoL) dan pengalaman kesejahteraan kesihatan dalam kalangan wanita 
China dengan MBC. Oleh itu, kajian ini bertujuan untuk meneroka QoL dan 
pengalaman kesejahteraan penyakit dalam kalangan wanita MBC menjalani 
kemoterapi di Beijing, China.  
 Pendekatan kaedah campuran telah digunakan dalam dua fasa, dengan kaji 
selidik 176 wanita MBC (kuantitatif) diikuti dengan temubual bersemuka secara 
mendalam dengan 20 wanita MBC (kualitatif) di Hospital Kanser Universiti Beijing. 
QoL diukur menggunakan European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30) dan modul spesifik 
payudara (QLQ-BR23) versi China. DASS-21 (Skala-21 kemurungan, kebimbangan 
dan tekanan) telah digunakan untuk mengukur tahap kemurungan, kebimbangan dan 
tekanan. Disamping itu, gaya menangani diukur menggunakan Brief COPE versi 
China. Menggunakan kaedah persampelan bertujuan, 36 temubual separa berstruktur 
yang melibatkan 20 wanita MBC telah dijalankan bagi meneroka penceritaan QoL 
berkenaan pengalaman kesejahteraan kesihatan dan strategi menangani. Analisis 
diskriptif, kolerasi dan regresi linear umum (GLR) untuk data kuantitatif dan analisis 
tematik (perbandingan konstan) digunakan untuk data kualitatif.  
 xii 
 
 Dapatan kuantitatif menunjukkan bahawa 63.6% daripada wanita MBC 
mempunyai QoL yang rendah (≤50), 52.3% mengalami kemurungan, 60.2% 
mempunyai kebimbangan dan 36.9% mengalami tekanan. GLR mendedahkan 
bahawa penjangka QoL adalah umur (p=0.003), status perkahwinan (p=0.028), 
pendapatan bulanan (p=0.020), kefungsian fizikal (p=0.0006), kefungsian emosi 
(p=0.037), sakit (p=0.028), dyspnea (p=0.028) dan kehilangan selera makan 
(p<0.001). Kesemua lapan penjangka ini menjelaskan 43.7% daripada QoL global. 
Penjangka untuk kemurungan adalah kualiti perkahwinan yang teruk, pengekspresian 
perasaan, menyalahkan diri sendiri dan pengunduran tingkahlaku. Disamping itu, 
reframing positif berkadaran negatif dengan kemurungan. Kesemua varian yang 
menentukan kemurungan (R2) adalah 35.6%. Status perkahwinan, menyalahkan diri 
sendiri dan pengunduran tingkahlaku adalah penjangka kebimbangan dan 
menjelaskan 25.2% kepada kebimbangan dalam kalangan wanita MBC. Kualiti 
perkahwinan yang teruk, menyalahkan diri sendiri, penafian dan pengunduran 
tingkahlaku adalah penjangka tekanan dan semua penjangka tersebut menyumbang 
kepada 35.4% varian tekanan. Tiga tema muncul daripada data kualitatif: kehidupan 
dengan ketidakpastian kesejahteraan/kesihatan, pengalaman peralihan 
kesejahteraan/kesihatan dan strategi menangani kesejahteraan kepada kesihatan. 
 Dapatan kajian ini menunjukkan bahawa kesejahteraan fizikal dan psikologi 
memberi kesan kepada QoL, kemurungan, tekanan, kebimbangan dan gaya 
menangani dalam kalangan wanita China dengan MBC. Oleh itu, terdapat keperluan 
untuk professional penjagaan kesihatan dan penggubal polisi kesihatan untuk 
merancang program dan intervensi sokongan yang sesuai bagi mengurangkan 
symptom dan meningkatkan QoL wanita MBC.  
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QUALITY OF LIFE AND ILLNESS EXPERIENCES AMONG 
METASTATIC BREAST CANCER WOMEN UNDERGOING 
CHEMOTHERAPY IN BEIJING: A MIXED METHODS STUDY 
 
ABSTRACT 
 
Metastatic breast cancer (MBC) is an incurable illness with a median survival time 
ranging between 2 to 4 years following diagnosis. Research to date has limited 
focused on Chinese MBC women’s quality of life (QoL) and illness experiences. 
Thus, this study aimed to explore QoL and disease experience among MBC women 
undergoing chemotherapy in Beijing, China. 
A mixed methods approach was employed in two phases, with a survey of 
176 MBC women (quantitative) followed by in-depth face-to-face interviews with 20 
MBC women (qualitative) at Beijing University Cancer Hospital. QoL was measured 
using the Chinese version of the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and its breast-specific 
module (QLQ-BR23). The DASS-21 (Depression, Anxiety, and Stress Scale-21) was 
used to measure the degree of depression, anxiety, and stress, whilst the coping styles 
were measured using the Chinese version of Brief COPE. Using purposive sampling, 
36 semi-structured interviews involving 20 MBC women were conducted to explore 
QoL narration of illness experiences and coping strategies. Descriptive, correlation, 
and general linear regression (GLR) analyses of quantitative data and thematic 
analysis (constant comparative) of qualitative data generated the findings. 
Quantitative findings indicated that 63.6% of MBC women have low QoL 
(≤50), 52.3% have depression, 60.2% have anxiety and 36.9% have stress. GLR 
 xiv 
 
revealed that predictors of QoL including age (p=0.003), marital status (p=0.028), 
monthly income (p=0.020), physical functioning (p=0.006) and emotional 
functioning (p=0.037), pain (p=0.028), dyspnea (p=0.028) and appetite loss 
(p<0.001). All these eight predictors explained 43.7% of the global QoL. Predictors 
of depression include poor marriage quality, venting, self-blame and behavioral 
disengagement. Also, depression was negatively associated with positive reframing. 
All the variances determined the depression (R2) were 35.6%. Marital status, self-
blame and behavioral disengagement were the predictors of anxiety and explained 
25.2% variance of anxiety in MBC women. Poor marriage quality, self-blame, denial 
and behavioral disengagement were the predictors of stress; all those predictors 
accounted for 35.4% variance of stress. Three themes emerged from the qualitative 
data: “living with illness/wellness uncertainty”, “illness/wellness transition 
experience” and ‘illness to wellness coping strategies”. 
This study suggests that physical and psychological wellbeing have an impact 
on the QoL, depression, stress, anxiety and coping among Chinese MBC women. 
Thus, there is a need for healthcare professionals and healthcare policy makers to 
plan for the appropriate supportive program and interventions to alleviate symptoms 
and improve QoL for MBC women.  
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CHAPTER 1 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Introduction  
Metastatic breast cancer (MBC) represents a significant public health burden across 
the globe. Living with MBC can be frightening as this disease is the most advanced 
stage of breast cancer (BC). According to International Agency for Research on 
Cancer (IARC), new cases of diagnosed BC were estimated 1.67 million in 2012 
worldwide (Ferlay et al., 2015). Between the year 2008 and 2012, the rate of new BC 
cases increased while mortality remained relatively stable based on Global Burden of 
Cancer Study (GLOBOCAN) data from more than 180 countries (Ferlay et al., 2010; 
Ferlay et al., 2015). Nevertheless, as country-specific trends differ widely and may 
vary from global trends, it should be acknowledged that there are wide differences in 
both incidence and mortality rates (DeSantis et al., 2015; Ferlay et al., 2015). 
Furthermore, as reported by the Global Status of Metastatic Breast Cancer Decade 
Report 2005 to 2015, there is no cure for MBC (Cardoso et al., 2014). The report 
highlighted that there would be an increase of 43 percent in BC associated deaths 
across the globe from the year 2015 to 2030, of which the majority are a 
consequence of metastatic disease (Breast Cancer Vision, 2016).  
China, recognized as one of the biggest less-developed countries, has an 
immense cancer problem with BC incidence increased by 80% in young women in 
the past two decades (Zhang et al., 2010) and the primary type of cancer detected in 
females (Wang et al., 2012b). Besides, the disease accounts for 15% among all kinds 
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of cancer in female (Chen et al., 2016). In China, 169,000 new cases of BC were 
diagnosed in 2008. As reported by Zheng et al. (2013), BC was higher in an urban 
area and since 1973, the death rate from BC has unceasingly increased in China 
(Zheng et al., 2011). According to Linos et al. (2008), the upsurge of BC is pervasive 
throughout China while the trend in BC incidence and the mortality rate is likely to 
increase. The population at risk for BC was those women aged 40 to 70 (Zhang et al., 
2012).  
According to Chen et al. (2016) review covering women’s issues changing 
women’s live on BC in China concluded that detection, diagnosis, and treatment 
of breast cancer urgently need improvement. Misdiagnosis, long wait times, drastic 
surgeries, excessive chemotherapy (CT) and, perhaps most significant, catastrophic 
expense had led many of Chinese women to avoid detection in the first place, often 
seeing it as little more than a death sentence. Despite the high incidence of BC 
reported, there is a lack of significance in diagnosis and detection of BC in its early 
stages. According to Alsop et al. (2012), in Western countries, there were many 
resources made available for patient education, awareness of BC detection and 
therapeutic options. Contra to Western countries, a big proportion of BC women in 
China are diagnosed with Stage III/IV disease (Chen et al., 2016). Apart from the 
stage IV BC as the first diagnosis, more than 30% of BC women who are in early 
stage of BC will ultimately progress to metastatic disease (Lu et al., 2009; Redig and 
McAllister, 2013). As reported, the population of MBC survivors is increasing 
gradually with median survival 2-3 years for MBC women (Cardoso et al., 2014). In 
terms with Ganz and Stanton (2015), the scope is wider, and cancer patients can 
survive longer at least partly attributable to the accessibility of effective target 
therapy, complementary and alternative medicine at an early stage.  
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This thesis describes and explains the Chinese MBC women’s quality of life 
(QoL) and illness experiences undergoing chemotherapy (CT) at the Beijing Cancer 
Hospital, China. This present study reports a gap in knowledge about what QoL and 
its relationship with illness experiences for Chinese MBC women undergoing CT in 
China. Presently, no crucial evidence is made available in this particular study. 
Despite developments in the medical and clinical management of MBC, there is a 
dearth of knowledge and information about the QoL and illness experiences among 
MBC women in China. Furthermore, MBC women who underwent CT treatment 
were known to have confronted element in QoL and illness experiences which 
contribute to the psychological distress, anxiety, stress, and coping (Saniah and 
Zainal, 2010; Reed et al., 2012). According to the researchers, women diagnosed 
with MBC and suffering from this illness trajectory has potential implications for 
health service provision and care (Saniah and Zainal, 2010; Reed et al., 2012). 
Measuring QoL in MBC women has been the focus of the importance of which, is 
critical for health care practice and research study in assessing treatment outcomes. 
Thus, it was important to explore deeply MBC women’s QoL and how the 
development of MBC influence their illness experiences over time. 
1.2 Background of the Study 
China, one of the biggest less-developed countries, has an immense cancer 
problem with BC incidence increased by 80% in young women in the past two 
decades (Zhang et al., 2010) and BC account for 14.2% among all types of cancer. 
According to the report in the Global Cancer Statistics 2008, the most commonly 
diagnosed malignancy among women across the globe with incidence reaching 
nearly 1.38 million per year and 4.6 million mortality was BC (Ferlay et al., 2010). 
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MBC and its treatment carry pivotal life-changing events which prompt 
women to adapt to it. Along with the advancements in the treatment of MBC such as 
target therapy, more rational and personal CT regimen, many patients were able to 
survive longer on an effective medicine regimen. However, some were found living 
with the disease trajectory along with the treatment and an inadequate response to the 
drug regimen. MBC women suffer from physical and psychosocial issues, which 
associated with the illness itself and the treatment and the uncertainty of the living in 
the shadow of death (Bell and Ristovski-Slijepcevic, 2011; Mosher et al., 2013b). 
Health professionals usually focus on the physical manifestation of the illness and 
side effects of the treatment; however, little attention was paid on the psychological, 
social, and spiritual wellbeing (Kamal et al., 2014).   
In China, approximately 169,000 new BC cases diagnosed in 2008, and the 
number of mortality has increased dramatically in urban areas than in the countryside 
(Zheng et al., 2011). Ziegler et al. (2008) reported that the incidence of BC in China 
will be 87.8 per 100,000 women by the year 2021. Their findings support the 
Chinese National Family Planning and Reproductive Health Survey (NFPRHS) 
which also found similar prevalence about the BC incidence rate in China. Coincides 
with NFPRHS’s analysis, new cases of BC incidence will increase dramatically in 
urban and rural areas across China (Linos et al., 2008). 
According to Zhang et al. (2012), BC was the second cause of incidence rates 
among all the cancers in China, with both increasing incidences of morbidity and 
mortality in next two decades. They note that Chinese population at risk for BC were 
those women aged 40 to 70 years (Zhang et al., 2012). The International Agency for 
Research on Cancer (IARC) indicates that the incidence of BC had been sharply 
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increased from 1985 to 2005 in China, and BC is the commonest among women in 
Beijing as shown in Figure 1.1 (International Agency for Research on Cancer, 2014).  
 
 
 
Figure 1.1 Estimated 5-year prevalence cancer cases among women in Beijing, 
China 
[Source: International Agency for Research on Cancer (2014)] 
 
 
There are two cancer specialized hospitals in Beijing: Beijing Cancer 
Hospital (also known as Peking University Cancer Hospital) and Cancer Hospital 
Chinese Academy of Medical Sciences. Beijing Cancer Hospital is a teaching and 
specialist hospital located in Beijing, China (see Figure 1.2). The hospital is affiliated 
with the Peking University. The hospital is a teaching and research-based hospital, 
and has earned a reputation as one of China’s leading cancer hospitals. The hospital 
offered an extensive range of services for oncology patients, supported by highly 
qualified health care specialists. At the Beijing Cancer Hospital, research into the 
underlying oncologic process and clinical investigation on specific cancer disease go 
hand in hand, and the hospital is at the forefront of biomedical research, driving the 
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discoveries that lead to new ways to prevent and treat cancer (Record Statistic 
Beijing Cancer Hospital, 2012 – 2013, China). Beijing Cancer Hospital was selected 
as the choice of study setting in this study because of the hospital recognition as a 
major referral hospital with 790 beds and an annual admission of approximately 
1,400 BC patients for medical and surgical management; including palliative care. In 
addition, the hospital is a renowned cancer center in China devoted exclusively to 
cancer care, cancer education, and cancer research and cancer prevention. 
 
 
Figure 1.2 Beijing Cancer Hospital, China 
(Source: Google map) 
 
Living with MBC can be devastating. The adverse psychological impact of 
BC is often associated with poor QoL (Montazeri, 2008; Al-Azri et al., 2009; 
Hopwood et al., 2010; Gaston-Johansson et al., 2013). With the increasing number 
of BC patients, the survivors are growing. Younger BC women undergoing CT were 
significantly associated with poorer QoL (Ganz et al., 2003). It was also indicated 
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that BC women under CT experiences increased psychological disease and little QoL 
(Schreier and Willians, 2004; So et al., 2010; Liu et al., 2013).  
The Psycho-Oncology Co-operative Research Group (PoCoG) in Australia 
reported that CT can affect patient’s QoL in a range of ways such as lessening 
symptoms, halting or reversing deteriorations in functioning through treatment 
(PoCoG, 2015). BC patients appear to experience problems in multiple QoL domains 
following the CT treatment.  
Assessment of a patient's QoL is now conceptually viewed as necessary, 
evidence had shown that CT can be offered to sustain survivorship and QoL. In a 
review of QoL studies among BC survivors, researchers indicated a need to explore 
BC patients’ QoL associated with treatment modalities. However, only a few studies 
have examined the association between socio-demographic, the effects of 
psychosocial factors on QoL and MBC women survivors undergoing CT in China 
despite routine QoL assessments is recommended in clinical practice (Valderas et al., 
2008; Engelen et al., 2012). Furthermore, there is a dearth of studies using the mixed 
method approach to explore the QoL and illness experiences of Chinese MBC 
women undergoing chemotherapy in Beijing, China. 
1.3 Rationale for the Study  
The experience of living with MBC exposes patients to a wide variety of 
physical, psychological, social and spiritual issues. MBC patients are facing 
numerous challenges, including QoL concerns derive from the disease and treatment-
related side effects. Many of them are experiencing an enhanced awareness of life’s 
brevity; and many of them are prone to have emotional distress, such as symptoms of 
stress, anxiety, depression and fear of death (Mosher et al., 2013b).  
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Studies show that younger age, a dearth of social support for example poor 
financial situation, is associated with greater anxiety level and depression; including 
poor QoL in cancer patients (Shen et al., 2012; Panjari et al., 2014). The adverse 
effects of treatment-related symptoms and CT treatment have been linked with QoL 
(Safaee et al., 2008; Takahashi et al., 2008). Measuring QoL in MBC patients is 
essential to explore CT treatment outcomes. MBC women who are maladaptive of 
the diagnosis, treatments, and prognosis may suffer from psychological distress, 
which predicts poor QoL. It is important to understand how MBC women view their 
illness and lives, their QoL, illness experiences, and coping strategies. However, 
many researchers have tried to know MBC patients’ emotional response, coping 
strategies and their QoL predominantly in Western countries. In spite of human are 
equal; in every culture, a particular set of virtues prized above all others; and this is 
the case when one compares the East and the West. Cultural differences between 
Chinese and Western culture are evident. The people of China may have a different 
emotional response and coping strategies in facing MBC and its treatment. Social, 
cultural influences on BC and health care practices were one of the bases that shape 
Chinese women’s behavior (Shang et al., 2015). Therefore it is important to conduct 
this research study to untapped the issue of the knowledge gap within eastern cultural 
context.  
1.4 Problem Statement 
MBC itself and the CT treatment are known to affect the QoL of cancer 
patients. Measuring QoL in MBC women has been the focus of research lately to 
assess treatment modalities outcomes due to the growing number of MBC patients in 
China. Also, MBC affects women’s depressing, anxiety and coping and therefore 
studying QoL in women who either lose their lives or undergoing CT is critical. The 
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situation assumed that women play a major role in the family, as a mother, and or a 
wife. Examining QoL outcome has become an important topic in MBC care 
especially those that stresses on exploring MBC women’s voice in their illness 
experiences undergoing CT treatment. The time of diagnosis and disease progression 
are transition periods of poor adjustment and decreased QoL in MBC patients. 
Knowledge about QoL and following metastasis undergoing CT may be beneficial 
for improving clinical care. The present study, therefore, aims to explore this by 
employing a mixed method research approach to investigate the MBC patients’ QoL 
and illness experiences undergoing CT. Consequently, this led to the researcher to 
develop the research questions of this study.  
1.5 Research Questions 
  Quantitative research questions: 
a) What is the QoL in women diagnosed with MBC undergoing chemotherapy in 
Beijing Cancer Hospital, China? 
b) What is the psychological distress (Depression, Anxiety, and Stress) among 
MBC women? 
c) How do they cope with their MBC diagnosis and treatment? 
d) What are the associations between socio-demographic/medical characteristics 
and the QoL among MBC women undergoing chemotherapy? 
e) What are the associations between socio-demographic/medical characteristics 
and coping styles and psychological distress (depression, anxiety, and stress) 
of MBC women undergoing chemotherapy? 
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Qualitative Research Question: 
a) What is the MBC women’s perception of their QoL after undergoing 
chemotherapy? 
b) How are their experiences after diagnosed with MBC and undergoing 
chemotherapy? 
c) What coping strategies do they adopt during their illness trajectory? 
d) What kind of support do they need? 
1.6 Aims of the Study 
This study aimed to explore QoL and illness experiences among metastatic breast 
cancer women undergoing chemotherapy in Beijing, China. 
1.6.1 Specific Quantitative Objectives 
a) To determine the quality of life (QoL), depression, anxiety, stress and coping 
among MBC women undergoing chemotherapy in Beijing; 
 
b) To explore the correlation between QoL and depression, anxiety and stress;  
 
c) To explore the correlation between coping strategies with depression, anxiety, 
and stress; 
 
d) To determine the association of socio-demographic characteristics (age, 
marital status, level of education, working status, household income and self-
evaluation of marriage quality) and medical characteristics (time since MBC 
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diagnosis, bone metastasis, lung metastasis, liver metastasis, brain metastasis, 
treatment lines, single or combine regimen and metastasis sites) with QoL; 
 
e) To determine the association of socio-demographic characteristics, medical 
characteristics and coping styles with psychological distress (depression, 
anxiety, and stress). 
1.6.2 Specific Qualitative Objectives 
a) To explore the MBC Chinese women’s QoL undergoing chemotherapy;    
 
b) To explore the MBC Chinese women’s illness experiences undergoing 
chemotherapy; 
 
c)  To explore the MBC Chinese women’s support needs; 
 
d) To explore the MBC Chinese women’s coping strategies. 
 
1.7  Research Hypotheses 
HA1: There is a significant association between socio-demographic 
characteristics (age, marital status, level of education, working status, 
household income and self-evaluation of marriage quality) and medical 
characteristics (duration of MBC diagnosis, bone metastasis, lung 
metastasis, liver metastasis, brain metastasis, treatment lines, single or 
combine regimen and number of metastasis sites) with QoL. 
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HA2: There is a significant association between socio-demographic 
characteristics, medical characteristics and coping styles with depression. 
 
HA3: There is a significant association between socio-demographic 
characteristics, medical characteristics and coping styles with anxiety. 
 
HA4: There is a significant association between socio-demographic 
characteristics, medical characteristics and coping styles with stress. 
1.8 Significance of Quality of Life Research in Metastatic Breast Cancer 
Trajectory 
Studying the oncological literature review indicates that researchers have 
focused particular attention to QoL in the last twenty years. The majority of the 
researchers contemplate that QoL is an important topic of interest to study when 
delivering care to breast cancer patients. Considering many studies on QoL 
conducted with BC patients, publications in which QoL among MBC women has not 
rigorously measured in China. Furthermore, in Beijing, approximately 35.5 per 
100,000 women suffer from BC. Also, surviving time for women with MBC has 
prolonged due to new and aggressive treatment modalities. The overall survival time 
has extended due to the medical development. The purposes of treatments for MBC 
women has lengthened their survival time and improve their QoL, therefore the 
general QoL especially more attention should pay on the psychosocial wellbeing. 
With aggressive therapy which may result in a longer lifespan survivorship, MBC 
women may experience devastating effects of CT and suffer from sequelae that 
affect their QoL (Khan et al., 2012). Previous studies have shown that exploring QoL 
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provides more information about symptoms than measuring adverse events alone 
(Huschka et al., 2007; Lemieux et al., 2011).  
Review of studies noted that QoL is a multifaceted and multidimensional 
concept, both is unique and personal (Huschka et al., 2007; Lemieux et al., 2011). 
Hence, data of QoL and illness experiences of MBC women undergoing treatment, 
especially for chemotherapy recipients, may provide evidence for clinical care to 
afford patient-centered solutions for an evidence-based selection of optimal treatment 
and psychosocial intervention.  
1.9 Definition of Operational Terms 
Following are the terms used in this study: 
QoL - According to WHOQOL Group (1998), the term Qol refers 
to a person’s perception of their status in life in the cultural 
context and value systems in which they live and about 
their goals expectations, standards, and concerns. In this 
study, QoL is a broad-ranging concept affected in a 
complex way by an individual MBC woman’s 
independence, social relationships and their relationship to 
salient features of their environment. 
 
Illness 
experiences 
- The term illness experiences refer to the ways in which 
people define and adjust to perceived interruptions to their 
health (Ritzer, 2007). In this study, illness experiences 
refer to the MBC Chinese women’s physical well-being, 
psychological reaction and the way of coping.  
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Anxiety - In this study, anxiety  refers to the MBC Chinese women 
feeling of restlessness, accompanied by dysphoria and 
somatic signs and symptoms of tension, focused on the 
apprehension of possible failure, misfortune, or danger 
(Colman, 2015) 
 
Major depression - In this study, it refers to syndrome experience that plague 
MBC patients such as depressed mood and/or anhedonia 
accompanied by alterations in appetite, sleep, activity 
levels and cognitive function (Miller et al., 2008).  
 
Stress  In this study, stress is measuring a state of persistent 
arousal and tension with a low threshold for becoming 
upset or frustrated (Lovibond and Lovibond, 1995a).  
 
Coping strategies - Coping strategies refer to psychological and behavioral 
efforts used to manage the specific external or internal 
demands that tax a person’s resources (Lazarus, 1991). In 
this study, it refers to the explicit efforts, both behavioral 
and psychological that MBC women used to control, abide, 
decrease or minimize /overcome psychological 
distress/stressful happenings. 
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Body image - Body image is a person’s perception of the aesthetics or 
sexual attractiveness of their own body. In this study, it 
refers to an MBC woman’s perceptions, thoughts, and 
feelings about his or her body (Grogan, 2007). 
 
Uncertainty - In this study, it refers to a cognitive, perceptual state that 
arrays from the feeling of just less than security to 
indistinctness; and it changes over time and accompanies 
by intimidating and/or positive feelings/emotions (Hilton, 
1994). 
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CHAPTER 2 
CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Introduction  
This chapter provides the literature review about the study: Quality of life (QoL) and 
illness experiences among metastatic breast cancer (MBC) women undergoing 
chemotherapy (CT), and more specifically among Chinese MBC women at Beijing 
Cancer Hospital. Reviewing the literature is to gain a thorough understanding of the 
research topic, identify impending areas for research and knowledge gaps that 
demand further investigation. By undertaking a literature review, it can help the 
researcher to unravel scientific evidence and information to a similar study done 
within the area and compare previous findings, to critique existing results and 
suggest further studies (Aveyard, 2014). This chapter also provides a summary of the 
quantitative and qualitative studies to inform, enhance, extend and supplement this 
study. The final section of this chapter discusses the conceptual framework guiding 
the data extraction process. 
2.2 Breast Cancer in China 
Globally, BC is a major public health issue and the incidence varies between 
less developed and developed regions. To date, BC represents one in four of all 
cancers. The GLOBOCAN 2012 database revealed a sharp rise in BC cases 
worldwide. The GLOBOCAN declared that approximately 1.7 million women were 
diagnosed with BC in 2012 while 6.3 million women were diagnosed with BC in the 
previous five years (Ferlay et al., 2015).  
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As published by IARC, the patterns in BC incidence highlighted an increased 
by 20%, while mortality were 14%. From 184 countries, women were diagnosed 
with BC in 140 countries across the world. The latest statistics as reported by the 
World Health Organization (2012) shows a global BC burden escalations to 14.1 
million new cases in 2012. Contra to WHO (2012) which shows an increased in BC, 
Wu et al. (2012) study identified a lower BC incidence rates compare to Western 
countries. Nevertheless, their research indicates that BC incidence among women has 
increased dramatically in the past 20 years in China.  
In China, BC was the primary type of cancer detected in females (Chen et al., 
2015) and expected account for approximately 15% of all types of newly diagnosed 
cancer among Chinese female (Chen et al., 2016). According to Chen et al. (2016), 
the incidence of BC in Chinese female was 268,600 and is the fifth cause of death 
among Chinese female with the mortality was 69,500 in 2015. 
In urbanized city China, BC is the most common cancer, and the disease is 
identified as the third leading cause of cancer-related mortality among women (Chen 
et al., 2016). According to (Fan et al., 2014), the burden from BC was reported to 
increase. About more than 1.6 million Chinese women are expected to develop BC. 
Along with the population, 1.2 million of Chinese BC women will have disease 
spread and die from MBC per year. As argued by Fan et al., a total of 12.2% were 
newly diagnosed BC. China's relative contribution to global rates is indicated to 
increase fast mainly due to the present population's rising socioeconomic status and 
unique reproductive patterns. Their review includes disparities between China and 
high-income countries. The report also includes younger age at onset of BC; the 
individual one-child policy; lower rates of provision and uptake for screening for 
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BC; delays in diagnosis that result in more advanced stage of disease at presentation; 
inadequate resources; and a lack of awareness about BC in the Chinese population.  
2.2.1 Risk Factors for Breast Cancer 
There is no exact cause of BC. However, there are many risk factors known 
to increase the probability of a woman developing to BC. Therefore, it is important 
to distinguish the risk factors of BC to provide individualized care for BC patients 
for example age, genetics, hormonal factors, radiation exposure, and other factors. 
Most women diagnosed with BC in 40 or over 40 years old, but the majority of cases 
occur in women over 50 years old. In China, women aged 45-59 years old are at a 
higher risk of BC diagnosis (Chen et al., 2016). A female who has a mutation in 
BRCA1 or BRCA2 tumor expression genes and personal or family history of cancer 
are at high risk to the development of BC. An increased lifetime exposure to estrogen 
and progesterone as in those with early menarche or late menopause are prone to 
have a high risk of developing BC. Also, risk factors include nulliparity or first full-
term pregnancy after 30 years old places a woman at increased risk, and oral 
contraceptives or hormone replacement therapy users and radiation exposure. Other 
factors were benign breast disease, obesity, dietary fat, alcohol consumption, and 
socioeconomic status are also the risk factors of BC, ethnicity is associated with BC 
risk (Martha et al., 2007). 
2.2.2 Staging of Breast Cancer 
According to American Joint Committee on Cancer (AJCC), BC stage is 
classified based on the tumor, nodes, metastasis (TNM) as follows (Egner, 2010) (see 
Table 2.1):  
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Table 2.1 Breast cancer staging 
Stage 0 Tis N0 M0 
Stage IA T1* N0 M0 
Stage IB T0 N1mi M0 
T1* N1mi M0 
Stage IIA T0 N1** M0 
T1* N1** M0 
T2 N0 M0 
Stage IIB T2 N1 M0 
T3 N0 M0 
Stage IIIA T0 N2 M0 
T1* N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Stage IIIB T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
Notes: * T1 includes T1mi; **T0 and T1 tumors with nodal micrometastases only 
are excluded from Stage IIA and are classified Stage IB; M0 includes M0(i+). 
Sources:[https://cancerstaging.org/references 
pools/quickreferences/Cancer%20Staging%20poster%20Picture%20Library/BreastP
oster1.jpg] 
 
2.3 Metastatic Breast Cancer 
Metastatic breast cancer (MBC) is a treatable but incurable disease, the 
prognosis can be highly variable and heterogeneous to an individual, and the median 
survival age is 2 to 3 years (Cardoso et al., 2014). Apart from the stage IV breast 
cancer as the first diagnosis, more than 30% of BC women with an early stage of BC 
will ultimately develop metastatic disease (Lu et al., 2009; Redig and McAllister, 
2013). The treatments modalities for MBC women and their outlook varies, with 
some women living for years on stable medical regimens, while some live with a 
changing target of this deadly disease with aggressive treatments modalities and 
uneven response to treatment. The BC cells typically spread to bone, lung, liver and 
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brain. Multiple metastases are more common than the single metastasis site (Saha et 
al., 2013). 
The symptom burden of bone metastases increased. The symptom includes 
pain, hypercalcemia, pathologic fractures and spinal cord compression. It is striking 
that bone pain exists in MBC women with bone metastasis. Agents such as 
Bisphosphonates and Denosumab; and radiotherapy are implementing to control the 
disease (Rizzoli et al., 2013). Utilizing the bisphosphonates contributed to better 
global QoL, physical, social and emotional functioning (Diel et al., 2004). 
Bisphosphonates are widespread used among breast cancer women with bone 
metastasis. The side effects of bisphosphonates consist of fever, arthralgia, and 
gastrointestinal symptoms. Pain assessment and management among MBC women 
with bone metastases are necessary. 
Lung metastases present symptoms encompassing pleuritic pain, dry cough, 
shortness of breath and exertional dyspnea. A part of women also has heaviness 
feeling or pain in the chest. All these symptoms caused by the metastases on lung 
tissue, pleural effusion or airway obstruction. And some of MBC women with early 
lung metastasis are surviving without obvious symptoms.  
It is clear that the symptoms of liver metastases include abdominal fullness, 
pain, jaundice, pruritus, nausea, anorexia et al. Based on the specific symptom 
management, the administered drug were antiemetics, analgesics, and antihistamines. 
Obstruction of portal veins or liver failure resulting from liver metastasis could lead 
to ascites. It appears on some of MBC women, which may affect their QoL and leads 
to numerous symptoms such as abdominal distention, anorexia, nausea, vomiting, 
fatigue, lower extremity edema and shortness of breath (Tapping et al., 2014). 
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Paracentesis and diuretics generally are used for mitigating the symptoms. The 
prognosis is poor when the ascites emerges (Stephenson and Gilbert, 2002).  
It was reported that brain metastasis affects 10% to 15% of breast cancer 
metastasis patients (Lin et al., 2013). Unfortunately, brain metastasis presents a poor 
prognosis. Symptoms of brain metastases include neurologic dysfunction and 
functional decline. Sometimes the brain metastasis affects the survivors’ body 
controlling leading to movement imbalance (Mosher et al., 2013b). A seizure 
happens on a small set of brain metastasis survivor (Feyer et al., 2010). All these are 
difficult to control and can lead patients and caregivers to distress. It is necessary to 
palliate the headaches, nausea, vomiting, and reduce the brain swelling. 
Administering anticonvulsants to prevent seizure had been practiced to some extent 
even though the evidence is limited (Cleary et al., 2013). 
The treatment for MBC women is a complex and intricate result from the 
different metastatic sites, disease-free interval, medication taken and the pathology 
type. Regardless of MBC patients may have a good response to the medication 
effectively for a long time, it is also possible they have to move on to different 
regimens.  
2.4 Comprehensive Cancer Care  
According to the Education in Palliative and End-of-Life Care for Oncology 
(National Cancer Institute, 2015), comprehensive cancer care encompasses anti-
cancer therapy, supportive care, palliative care and bereavement care (see Figure 2.1). 
Self-help, support, self-involvement, information giving, psychological support, 
symptom control, social support, rehabilitation, complementary therapies, spiritual 
support, palliative care, end-of-life and bereavement care should be involved in the 
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comprehensive cancer care. It is important and worthwhile to apply compassionate 
and palliative care for MBC women with health related problems early on. 
 
 
Figure 2.1  Comprehensive cancer care 
Source: [http://www.cancer.gov/resources-for/hp/education/epeco/self-study/plenary-
2/plenary-2.pdf] 
 
The supportive and palliative care are indispensable parts of the 
comprehensive care for MBC women. There is an increasing argument that BC 
patients should be informed regarding support and palliative care services once a 
diagnosis of the advanced disease was made, or soon after the start of tumor- specific 
treatment (Cleary et al., 2013). The definition of supportive care is care that helps the 
patient and their family to cope with cancer and treatment. It is from the disease 
diagnosis, through the process of diagnosis and treatment modalities, to cure, illness 
or death and into bereavement (Hui et al., 2013). The implication of this supportive 
care is that it helps the BC patient to make the most of the benefits of treatment 
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modalities and to survive with the effects of the disease. Apart from that, a cancer 
patient was given an equal priority alongside diagnosis and treatment modalities.  
Palliative care is an important approach to cancer care. This method is noted 
to improve the QoL among patients and their families when faced with challenges 
associated with life-threatening illness, prevention, and relief of suffering using early 
identification and impeccable assessment and treatment of physical symptoms 
especially pain, physical, psychosocial and spiritual wellbeing. Palliative care 
supports life and regards dying as a normal process. The care also offers a support 
system to help the family cope during the patients’ illness and in their own 
bereavement. It was applicable in early processes of disease and in conjunction with 
other therapies intended to prolong life, such as chemotherapy or radiation therapy, 
and includes those investigations needed to better understand and manage distressing 
clinical complications (WHO) and affordable for the MBC women at the beginning 
of the treatment course (Ganz and Stanton, 2015). Patients who were referred to 
palliative care early in the illness trajectory had better end-of-life care compared with 
patients with a later referral (Hui et al., 2014; Zimmermann et al., 2014). The 
integration of early palliative care and oncology care for metastatic cancer patients 
benefits their QoL and psychological wellbeing (Nipp et al., 2016b). Decreasing 
aggressive medical interventions and hospital costs, reducing the inpatient 
admissions and increasing the satisfaction of hospital service result from the 
palliative care service as well (Meyers et al., 2011; Parikh et al., 2013; May et al., 
2016). Outpatient palliative care services are recommended to the gynecological 
cancer patients with severe symptom burden regardless of the stage or site of disease 
(Lefkowits et al., 2014). 
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Approximately 40,000,000 people need palliative care every year, 78% of 
them are from low- and middle-income countries (WHO, 2015). The integration of 
supportive and palliative care for cancer patients are supported inadequately in China 
(Hu and Feng, 2016). In light of the findings from the Economist Intelligence Unit, 
China ranks 71st of 80 countries for palliative care and end-of-life health care 
programs. The effect of traditional view on death may be one of the reasons hinders 
patients to accept palliative care emotionally in China. Strong taboos against 
discussion of death were evidence in Chinese culture (Xiao et al., 2012). One study 
conducted in Asia revealed that patients perceived the palliative care as death, 
hopeless, dependency and end of life comfort care for inpatients. The desperate 
feeling was engendered by receiving the palliative care among patients and their 
family. On the other hand, Chinese physicians provide inadequate end-of-life care 
may because of the undertrained palliative care education (Jiang et al., 2011). The 
advocating and education relevant to early palliative care still need to be conducted 
on the public, patients and healthcare providers (Zimmermann et al., 2016). 
Furthermore, the recommendations suggest integrating physical symptom 
management, pain management, administration of monitoring and documentation, 
psychosocial care, spiritual care for the patients. The researcher recommends that 
China should implement ambulatory palliative care programs for the sake of 
improving patients’ QoL, consoling families and achieving cost-effective treatments 
course (Follwell et al., 2009; Fan et al., 2014).  
2.5 Quality of life in Metastatic Breast Cancer Women 
According to WHO Quality of Life (WHOQOL) group, QoL refers to an 
individual’s perception of their position in life in the context of culture and value 
systems in which they live and to their goals, expectations, standards, and concerns. 
